Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
Top Cited Papers
Open Access
- 15 March 2003
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 111 (6) , 821-831
- https://doi.org/10.1172/jci200316069
Abstract
Psoriatic arthritis (PsA) is an inflammatory joint disease characterized by extensive bone resorption. The mechanisms underlying this matrix loss have not been elucidated. We report here that blood samples from PsA patients, particularly those with bone erosions visible on plain radiographs, exhibit a marked increase in osteoclast precursors (OCPs) compared with those from healthy controls. Moreover, PsA PBMCs readily formed osteoclasts in vitro without exogenous receptor activator of NF-κB ligand (RANKL) or MCSF. Both osteoprotegerin (OPG) and anti-TNF antibodies inhibited osteoclast formation. Additionally, cultured PsA PBMCs spontaneously secreted higher levels of TNF-α than did healthy controls. In vivo, OCP frequency declined substantially in PsA patients following treatment with anti-TNF agents. Immunohistochemical analysis of subchondral bone and synovium revealed RANK-positive perivascular mononuclear cells and osteoclasts in PsA specimens. RANKL expression was dramatically upregulated in the synovial lining layer, while OPG immunostaining was restricted to the endothelium. These results suggest a model for understanding the pathogenesis of aggressive bone erosions in PsA. OCPs arise from TNF-α–activated PBMCs that migrate to the inflamed synovium and subchondral bone, where they are exposed to unopposed RANKL and TNF-α. This leads to osteoclastogenesis at the erosion front and in subchondral bone, resulting in a bidirectional assault on psoriatic bone.Keywords
This publication has 46 references indexed in Scilit:
- Cytokine-Activated Endothelium Recruits Osteoclast PrecursorsEndocrinology, 2001
- Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor κB ligand (RANKL)Clinical Science, 2000
- The Role of Receptor Activator of Nuclear Factor- B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone DiseasesJournal of Clinical Endocrinology & Metabolism, 2000
- Expression of functional RANK on mature rat and human osteoclastsFEBS Letters, 1999
- Human osteoclasts derive from CD14‐positive monocytesBritish Journal of Haematology, 1999
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- A New Mechanism of Bone Destruction in Rheumatoid Arthritis: Synovial Fibroblasts Induce OsteoclastogenesisBiochemical and Biophysical Research Communications, 1997
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Paravertebral ossification in psoriatic arthritis.Annals of the Rheumatic Diseases, 1965